No connection

Search Results

GDRX vs GYRE

GDRX
GoodRx Holdings, Inc.
BEARISH
Price
$2.16
Market Cap
$740.0M
Sector
Healthcare
AI Confidence
85%
GYRE
Gyre Therapeutics, Inc.
BEARISH
Price
$7.39
Market Cap
$711.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GDRX
24.0
GYRE
369.5
Forward P/E
GDRX
5.88
GYRE
123.17
P/B Ratio
GDRX
1.2
GYRE
6.37
P/S Ratio
GDRX
0.93
GYRE
6.11
EV/EBITDA
GDRX
8.35
GYRE
47.08

Profitability

Gross Margin
GDRX
92.77%
GYRE
95.36%
Operating Margin
GDRX
18.98%
GYRE
0.32%
Profit Margin
GDRX
3.82%
GYRE
4.31%
ROE
GDRX
4.54%
GYRE
8.21%
ROA
GDRX
4.75%
GYRE
4.93%

Growth

Revenue Growth
GDRX
-1.9%
GYRE
33.4%
Earnings Growth
GDRX
-9.7%
GYRE
--

Financial Health

Debt/Equity
GDRX
0.88
GYRE
0.01
Current Ratio
GDRX
2.61
GYRE
5.6
Quick Ratio
GDRX
2.1
GYRE
4.58

Dividends

Dividend Yield
GDRX
--
GYRE
--
Payout Ratio
GDRX
0.0%
GYRE
0.0%

AI Verdict

GDRX BEARISH

GDRX exhibits a fragile financial profile with a Piotroski F-Score of 4/9, indicating only marginal stability. The stock is currently trading at $2.16, which is a premium to its Graham Number ($1.91) and significantly above its growth-based intrinsic value ($0.63). Fundamental decay is evident through negative YoY revenue (-1.90%) and earnings growth (-9.70%), compounded by a streak of four consecutive earnings misses. With a 5-year price collapse of 94.7% and bearish insider sentiment, the data suggests a company in a structural decline.

Strengths
Exceptionally high gross margins (92.77%)
Strong short-term liquidity with a current ratio of 2.61
Low Price-to-Sales ratio (0.93) suggesting low valuation relative to revenue
Risks
Negative revenue and earnings growth trends
Consistent failure to meet analyst earnings estimates (0/4 last 4 quarters)
Severe long-term price erosion (-94.7% over 5 years)
GYRE BEARISH

GYRE exhibits significant financial fragility and valuation misalignment, evidenced by a weak Piotroski F-Score of 3/9 and a Graham Number of $0.72, which is a fraction of the current $7.39 price. While the company maintains a strong liquidity position with a Current Ratio of 5.60 and negligible debt, its valuation is extreme with a P/E ratio of 369.50. The disconnect between the intrinsic value ($0.14) and the market price suggests the stock is trading on speculative future expectations rather than current fundamentals. Technical trends are entirely bearish (0/100), and earnings consistency is poor, with only one beat in the last four quarters.

Strengths
Exceptionally low Debt/Equity ratio (0.01)
Strong short-term liquidity (Current Ratio 5.60)
High Gross Margin (95.36%) indicating strong product pricing power
Risks
Extreme valuation premium (P/E 369.50 vs Sector Avg 43.24)
Weak operational health as indicated by Piotroski F-Score (3/9)
Severe divergence between current price and Graham/Intrinsic value

Compare Another Pair

GDRX vs GYRE: Head-to-Head Comparison

This page compares GoodRx Holdings, Inc. (GDRX) and Gyre Therapeutics, Inc. (GYRE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile